35 patients will be selected (see sample calculation in Section 6) who have moderate to severe obstruction (FEV1 ≤ 70% predicted) and stable disease, as suggested by the absence of changes in medication in the last 4 weeks.
You may not be if
Ischemic heart disease, recent surgery, neuro-muscular or orthopedic that limit the performance of the protocol.
Patients will only be included in the study after signing the consent form.
Clareo Health | Effects of Laser Therapy on Muscle Function in COPD Patients
